Thromboxane Receptor Activates the AMP-Activated Protein Kinase in Vascular Smooth Muscle Cells via Hydrogen Peroxide
- 15 February 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 102 (3), 328-337
- https://doi.org/10.1161/circresaha.107.163253
Abstract
Thromboxane A2 receptor (TPr) stimulation induces cellular hypertrophy in vascular smooth muscle cells (VSMCs); however, regulation of VSMC hypertrophy remains poorly understood. Here we show that TPr stimulation activates AMP-activated kinase (AMPK), which in turn limits TPr-induced protein synthesis in VSMCs. Exposure of cultured VSMCs to either TPr agonists, IBOP and U46619, or exogenous hydrogen peroxide (H2O2) caused time- and dose-dependent AMPK activation, as evidenced by increased phosphorylation of both AMPK-Thr172 and acetyl-coenzyme A carboxylase–Ser79, a downstream enzyme of AMPK, whereas SQ29548, a selective TPr antagonist, significantly attenuated TPr-enhanced AMPK activation. In parallel, both IBOP and U46619 significantly increased the production of reactive oxygen species such as H2O2. Furthermore, adenoviral overexpression of catalase (an H2O2 scavenger) abolished, whereas superoxide dismutase (which catalyzes H2O2 formation) enhanced, IBOP-induced AMPK activation, suggesting that TPr-activated AMPK was mediated by H2O2. Consistently, exposure of VSMCs to either TPr agonists or exogenous H2O2 dose-dependently increased the phosphorylation of LKB1 (at serines 428 and 307), an AMPK kinase, as well as coimmunoprecipitation of AMPK with LKB1. In addition, direct mutagenesis of either Ser428 or Ser307 of LKB1 into alanine, like the kinase-dead LKB1 mutant, abolished both TPr-stimulated AMPK activation and coimmunoprecipitation. Finally, genetic inhibition of AMPK significantly accentuated IBOP-enhanced protein synthesis, whereas adenoviral overexpression of constitutively active AMPK abolished IBOP-enhance protein synthesis in VSMCs. We conclude that TPr stimulation triggers reactive oxygen species–mediated LKB1-dependent AMPK activation, which in return inhibits cellular protein synthesis in VSMCs.Keywords
This publication has 48 references indexed in Scilit:
- AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancerThe Journal of Physiology, 2006
- The Ca2+/Calmodulin-dependent Protein Kinase Kinases Are AMP-activated Protein Kinase KinasesJournal of Biological Chemistry, 2005
- Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cellsCell Metabolism, 2005
- Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinaseCell Metabolism, 2005
- Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophyCanadian Journal of Physiology and Pharmacology, 2005
- Possible involvement of the α1 isoform of 5′AMP-activated protein kinase in oxidative stress-stimulated glucose transport in skeletal muscleAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- AMP-activated protein kinase, super metabolic regulatorBiochemical Society Transactions, 2003
- Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartanBritish Journal of Pharmacology, 2001
- Glucose repression/derepression in budding yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratioCurrent Biology, 1996
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986